Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

U.S. District Court grants injunction for Sensipar patents

A U.S. District Court in Delaware today granted an injunction preventing Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals Industries Ltd., and Barr Laboratories, Inc. from commercializing generic versions of Amgen's Sensipar® (cinacalcet) until expiration of the drug's U.S. patents.

10 Jan 2011

Entelos receives U.S. Patent for Predictive Toxicology for Biological Systems

Entelos, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,853,406 entitled "Predictive Toxicology for Biological Systems" to the Company.

9 Jan 2011

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc. today announced the dosing of the first patient in the third phase 3 clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction (OBD) in subjects with chronic, non-cancer pain, excluding those taking methadone. The primary endpoint is an overall responder rate based on the change from baseline in the reported frequency of spontaneous bowel movements (SBMs).

7 Jan 2011

Amgen, Xencor collaborate to develop XmAb5871 for autoimmune disease

Amgen and Xencor, announced today that they will collaborate to develop XmAb®5871, an Fc- engineered monoclonal antibody dually targeting CD19 and CD32b. XmAb5871 is currently in late-stage preclinical development for the treatment of autoimmune diseases.

7 Jan 2011

Ligand, Chiva Pharmaceuticals enter strategic relationship to develop multiple Ligand assets, technology

Ligand Pharmaceuticals Incorporated announced today that it has entered into a strategic relationship with Chiva Pharmaceuticals, to develop multiple Ligand assets and technology in China and potentially worldwide.

7 Jan 2011

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b study of RDEA594 in combination with the current standard of care for the treatment of gout, allopurinol.

7 Jan 2011

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Isis Pharmaceuticals, announced today that it has added two new drugs to its development pipeline, ISIS-FGFR4Rx and ISIS-STAT3Rx.

7 Jan 2011

Medical experts issue warning about common practice of tablet splitting

Medical experts have issued a warning about the common practice of tablet splitting, after a study found that nearly a third of the split fragments deviated from recommended dosages by 15 per cent or more.

6 Jan 2011

InHealth awards grant to assess effects of hip replacement therapy on aging populations

The Institute for Health Technology Studies has awarded a grant of $240,000 to an international consortium of researchers, for a study that will assess the effects of hip replacement therapy on the employment and retirement decisions of older adults. Led by researchers at the Universit- Bocconi (Milan), the consortium also includes investigators at the University of York (York, UK), and the Johns Hopkins University School of Public Health (Baltimore).

6 Jan 2011

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Genentech, Inc., a member of the Roche Group, today announced that the United States Food and Drug Administration has extended the ACTEMRA (tocilizumab, RoACTEMRA in the European Union) label to include inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in adult patients with moderately to severely active rheumatoid arthritis, when given in combination with methotrexate.

6 Jan 2011

Mayo Clinic researchers estimate lifetime risk of developing rheumatoid arthritis in men and women

Mayo Clinic researchers have determined the lifetime risk of developing rheumatoid arthritis and six other autoimmune rheumatic diseases for both men and women. The findings appear online in Arthritis and Rheumatism.

6 Jan 2011

Carbylan completes enrollment in COR1.0 feasibility trial of Hydros and Hydros TA in knee osteoarthritis

Carbylan BioSurgery, Inc. announced today the completion of patient enrollment in their double-blinded, multi-center COR1.0 feasibility trial to evaluate the safety and effectiveness of two products - Hydros and Hydros TA Joint Therapies - in patients with osteoarthritis of the knee. Hydros and Hydros TA are next generation viscosupplement and viscosupplement/steroid combination products.

5 Jan 2011

Study finds fusion surgeries designed to alleviate pain from degenerating discs not effective

Alfred O. Bonati, M.D., internationally known orthopedic surgeon and founder of The Bonati Spine Institute, reports that, in his experience, the failure rates for open back surgery, as recently reported by the Ohio Bureau of Workers' Compensation, are not out of line.

5 Jan 2011

Tablet splitting leads to inaccurate dosages

5 Jan 2011

GLUMETZA tablets are now available to wholesalers and physicians

Santarus, and Depomed, today announced that supply of GLUMETZA® 500 mg to wholesalers and retailers has resumed. GLUMETZA is a once-daily, extended release formulation of metformin and is approved for use in adults with type 2 diabetes mellitus.

5 Jan 2011

Anaphylatoxin C5a may be responsible for devastating effects of atherosclerosis

For decades, doctors have looked at fitness levels, weight, and overall health risk factors for heart disease and stroke. Now, they may soon add a new risk factor to the list: activation of the complement system. The complement system is usually implicated in immune responses, but now there's a role for it in cardiovascular disease.

5 Jan 2011

New research finds physicians are not following standard care guidelines for OA

New research found clinicians who care for patients with osteoarthritis are likely not following standard care guidelines that are based on current medical evidence.

5 Jan 2011

Study: Stem cells play an unexpected role in male pattern balding

Given the amount of angst over male pattern balding, surprisingly little is known about its cause at the cellular level. In a new study, published in the Journal of Clinical Investigation, a team led by George Cotsarelis, MD, chair of the Department of Dermatology at the University of Pennsylvania School of Medicine, has found that stem cells play an unexpected role in explaining what happens in bald scalp.

5 Jan 2011

Clinicians rely upon analgesics and surgery; overlook exercise and weight loss for OA patients

New research found clinicians who care for patients with osteoarthritis (OA) are likely not following standard care guidelines that are based on current medical evidence. Researchers noted physicians were prescribing medications for pain and inflammation, or opting for surgical interventions rather than recommending weight loss plans or exercise programs to OA patients.

4 Jan 2011

Past smoking history does not affect RA patient's response to treatments

Patients with early rheumatoid arthritis (RA) who are current smokers were less likely to achieve good response to methotrexate (MTX) and tumor necrosis factor (TNF) inhibitors than those who never smoked. The study by researchers from Sweden also found that RA patients who smoked in the past did not experience a lower response to these therapies. Results of the 10-year study appear in the January 2011 issue of Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR).

4 Jan 2011

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

U.S. District Court grants injunction for Sensipar patents

Entelos receives U.S. Patent for Predictive Toxicology for Biological Systems

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

Amgen, Xencor collaborate to develop XmAb5871 for autoimmune disease

Ligand, Chiva Pharmaceuticals enter strategic relationship to develop multiple Ligand assets, technology

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Medical experts issue warning about common practice of tablet splitting

InHealth awards grant to assess effects of hip replacement therapy on aging populations

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Mayo Clinic researchers estimate lifetime risk of developing rheumatoid arthritis in men and women

Carbylan completes enrollment in COR1.0 feasibility trial of Hydros and Hydros TA in knee osteoarthritis

Study finds fusion surgeries designed to alleviate pain from degenerating discs not effective

Tablet splitting leads to inaccurate dosages

GLUMETZA tablets are now available to wholesalers and physicians

Anaphylatoxin C5a may be responsible for devastating effects of atherosclerosis

New research finds physicians are not following standard care guidelines for OA

Study: Stem cells play an unexpected role in male pattern balding

Clinicians rely upon analgesics and surgery; overlook exercise and weight loss for OA patients

Past smoking history does not affect RA patient's response to treatments

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in